COST-EFFECTIVENESS OF SECOND-LINE VASOPRESSORS FOR THE TREATMENT OF SEPTIC SHOCK

被引：0
|
作者：
Lam, Simon [1 ]
Barreto, Erin [2 ]
Scott, Rachael [3 ]
Kashani, Kianoush [3 ]
Khanna, Ashish [4 ]
Bauer, Seth [5 ]
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
[2] St Marys Hosp, Mayo Clin, Rochester, MN USA
[3] Mayo Clin, Rochester, MN USA
[4] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA
[5] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA
来源：
CRITICAL CARE MEDICINE | 2020年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
1630
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting
    Lauren, Brianna
    Ostvar, Sassan
    Silver, Elisabeth
    Ingram, Myles
    Oh, Aaron
    Kumble, Lindsay
    Laszkowska, Monika
    Chu, Jacqueline N.
    Hershman, Dawn L.
    Manji, Gulam
    Neugut, Alfred I.
    Hur, Chin
    JOURNAL OF ONCOLOGY, 2020, 2020
  • [42] COST-EFFECTIVENESS ANALYSIS OF ORAL SEMAGLUTIDE AS THE SECOND-LINE AND THIRD-LINE TREATMENT FOR TYPE 2 DIABETES PATIENT
    Tan, E. C. H.
    Yang, M. C.
    VALUE IN HEALTH, 2023, 26 (12) : S52 - S53
  • [43] The cost-effectiveness of adjunctive corticosteroids for patients with septic shock
    Thompson, Kelly J.
    Taylor, Colman B.
    Venkatesh, Balasubramanian
    Cohen, Jeremy
    Hammond, Naomi E.
    Jan, Stephen
    Li, Qiang
    Myburgh, John
    Rajbhandari, Dorrilyn
    Saxena, Manoj
    Kumar, Ashwani
    Finfer, Simon R.
    CRITICAL CARE AND RESUSCITATION, 2020, 22 (03) : 191 - 199
  • [44] Efficacy and cost-effectiveness of second-line chemotherapy in elderly patients with advanced gastric cancer
    K. Zhou
    F. Wen
    P. Zhang
    J. Zhou
    H. Chen
    H. Zheng
    Y. Yang
    Q. Li
    Clinical and Translational Oncology, 2017, 19 : 1117 - 1124
  • [45] COST-EFFECTIVENESS ANALYSIS OF CEMIPLIMAB AS SECOND-LINE THERAPY FOR RECURRENT CERVICAL CANCER IN JAPAN
    Maeda, Y. T. Shibata
    Chen, W.
    Morimoto, K.
    Moriwaki, K.
    Shimozuma, K.
    VALUE IN HEALTH, 2023, 26 (06) : S150 - S151
  • [46] COST-EFFECTIVENESS OF SECOND-LINE TREATMENT FOR ADVANCED ENDOMETRIAL CARCINOMA IN TAIWAN: LENVATINIB PLUS PEMBROLIZUMAB VERSUS DOXORUBICIN
    Chiang, S. T.
    Chueh, C. H.
    Ho, P. K.
    Wen, Y. W.
    Shiu, M. N.
    Liu, J. H.
    Li, W. H.
    Tsai, Y. W.
    VALUE IN HEALTH, 2023, 26 (12) : S63 - S63
  • [47] Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting
    Muresan, B.
    Mamolo, C.
    Cappelleri, J. C.
    Postma, M. J.
    Heeg, B.
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2021, 19 (06) : 929 - 940
  • [48] A COST-EFFECTIVENESS ANALYSIS FOR SECOND-LINE TREATMENT OF RELAPSED/REFRACTORY (RR) MULTIPLE MYELOMA (MM) IN THE UNITED KINGDOM
    Jiang, Y.
    Spencer, M.
    Gauthier, A.
    Pacou, M.
    VALUE IN HEALTH, 2011, 14 (07) : A452 - A452
  • [49] Meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticus
    Sanchez Fernandez, Ivann
    Gainza-Lein, Marina
    Lamb, Nathan
    Loddenkemper, Tobias
    NEUROLOGY, 2019, 92 (20) : E2339 - E2348
  • [50] Efficacy and cost-effectiveness of second-line chemotherapy in elderly patients with advanced gastric cancer
    Zhou, K.
    Wen, F.
    Zhang, P.
    Zhou, J.
    Chen, H.
    Zheng, H.
    Yang, Y.
    Li, Q.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (09): : 1117 - 1124
12345